Our newsmaker this hour, Dr. . Marty McCary, the FDA commissioner, marking his first 100 days on the job. It's been a busy few months with many changes at the agency from vaccines to staffing.Good morning, uh, doctor. Good morning, Joe. I don't maybe you've been on a few time.I don't I I don't remember, but we all went through uh that that period together, obviously, and and there's a lot of u of of a look back now at at at that period. you know, it's, you know, it's a it's a hot button issue and sometimes ...

Financial Performance - Total Adjusted EBITDA for Q2 2020 was $353 million, a decrease of $123 million from Q1 2020[13, 16] - Cash Available for Distribution (CAD) for the trailing twelve months ended June 30, 2020, was $103 million[8] - The company returned $69 million to shareholders YTD 2020 through dividends and share repurchases[9] Segment Results - Timberlands Adjusted EBITDA was $256 million, with 13 million tons harvested[11] - Wood Products Adjusted EBITDA was $109 million, with 249 MMBF lumber shipped[11] - Real Estate Adjusted EBITDA was $93 million, with 5K rural acres and 17 residential lots sold[11] Timberlands - Northern Region - Northern Timberlands Adjusted EBITDA was $127 million in Q2 2020, down from $199 million in Q1 2020[24, 27] - Northern sawlog harvest volume decreased to 303 thousand tons in Q2 2020 from 434 thousand tons in Q1 2020[27] - Northern sawlog price increased to $101 per ton in Q2 2020 from $95 per ton in Q1 2020[27] Timberlands - Southern Region - Southern Timberlands Adjusted EBITDA was $129 million in Q2 2020, down from $151 million in Q1 2020[31, 35] - Southern sawlog harvest volume decreased to 491 thousand tons in Q2 2020 from 548 thousand tons in Q1 2020[30, 35] - Southern sawlog price decreased to $43 per ton in Q2 2020 from $44 per ton in Q1 2020[30, 35] Wood Products - Wood Products Adjusted EBITDA was $109 million in Q2 2020, down from $132 million in Q1 2020[11, 46] - Lumber shipment volume decreased to 249 MMBF in Q2 2020 from 283 MMBF in Q1 2020[11, 42, 46] - Average lumber price increased to $412 per MBF in Q2 2020 from $396 per MBF in Q1 2020, a 4% increase[16, 42, 46] Real Estate - Real Estate Adjusted EBITDA was $93 million in Q2 2020, up from $73 million in Q1 2020[11, 59] - The company sold 5537 rural acres at an average price of $1784 per acre in Q2 2020[16, 54, 59] - The company sold 17 residential lots at an average price of $97059 per lot in Q2 2020[11, 58, 59] - The company announced the sale of approximately 72000 acres in Minnesota for ~$48 million, expected to close in Q4 2020[12, 47]

Will old folk catch the bug? https://t.co/XF2YyTGifS ...

New COVID-19 ‘Stratus’ Variant XFG Now In 38 Countries, WHO Monitoring https://t.co/ucfYkxdHEa ...

A new Covid-19 variant, officially known as NB.1.8.1 and nicknamed Nimbus, is now the most common strain in the US, according to the US Centers for Disease Control and Prevention. https://t.co/Io9WGz7HMV ...

EARNINGS RELEASE & FINANCIAL SUPPLEMENT First Quarter 2020 Corporate Profile We are the world's largest publicly traded REIT focused on the ownership, operation, acquisition and development of temperature- controlled warehouses. We are organized as a self-administered and self-managed REIT with proven operating, development and acquisition expertise. As of March 31, 2020, we operated a global network of 183 temperature-controlled warehouses encompassing over one billion cubic feet, with 161 warehouses in th ...

Key Takeaways Novavax reported strong immune responses from its COVID-19-influenza combo in adults 65 and older. The study guides the design for another late-stage trial that could support regulatory submissions. Novavax seeks partnerships to fund the development and commercialization of both vaccine candidates.Novavax (NVAX) announced encouraging results from an initial cohort of a late-stage study evaluating its experimental COVID-19-influenza combination (CIC) and stand-alone influenza vaccine candidat ...

Core Insights - Invivyd, Inc. announced the publication of results from its CANOPY Phase 3 clinical trial of pemivibart, demonstrating its safety and efficacy for the prevention of symptomatic COVID-19 in a contemporary U.S. population facing immune-evasive Omicron variants [1][4][6] Group 1: Clinical Trial Overview - The CANOPY Phase 3 clinical trial randomized 788 adult participants across 18 sites, focusing on immunocompromised individuals and those at risk due to regular face-to-face interactions [2][8] - The trial met all primary and exploratory endpoints during a significant COVID-19 transmission period in the U.S. from September 2023 to September 2024 [2][8] - Pemivibart showed an 84% relative risk reduction in symptomatic COVID-19 compared to placebo over six months [4][6] Group 2: Safety and Tolerability - Pemivibart was generally well-tolerated, with most adverse events classified as mild to moderate [3][6] - The most common treatment-emergent adverse events included infusion-related reactions, with a low incidence of anaphylactic reactions (0.6%) [3][12] - The safety profile aligns with previous clinical trials for COVID-19 monoclonal antibodies [3][6] Group 3: Regulatory and Future Implications - The trial's results support the emergency use authorization (EUA) of PEMGARDA (pemivibart) for pre-exposure prophylaxis in certain immunocompromised patients [2][10] - The publication aims to educate clinicians on the potential of monoclonal antibodies in combating COVID-19, particularly for immunocompromised individuals [5][7] - Invivyd plans to leverage data from the CANOPY trial to expedite the approval of novel antibodies like VYD2311 [7][18]

A health worker prepares a dose of the Novavax vaccine as the Dutch Health Service Organization starts with the Novavax vaccination program on March 21, 2022 in The Hague, Netherlands.A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.Novavax can finally breathe a sigh of relief – at least a small one.The Food and Drug Administration approved the company's Covid-19 vaccine a ...

Invivyd (IVVD) FY 2025 Conference May 20, 2025 11:00 AM ET Speaker0 Not ready. Okay. Hello, everyone, and welcome to the third annual, HC Wainwright BioConnect Conference. I'm Patrick Trucchio, a senior health parent at HC Wainwright. It's my pleasure to, introduce you to the management of InVivid. I'm Katie Falzoni, senior vice president of finance and Robert Allen, CSO. So first, I think it'd be good to start out with, some background on Invivid platform and on the validation of this antibody platform. Sp ...